Abstract
Protein degradation is mediated predominantly through the ubiquitin–proteasome pathway. The importance of the proteasome in regulating degradation of proteins involved in cell-cycle control, apoptosis, and angiogenesis led to the recognition of the proteasome as a therapeutic target for cancer [1–6]. The proteasome is also essential for degrading misfolded and aberrant proteins, and impaired proteasome function has been implicated in neurodegerative and cardiovascular diseases [7, 8]. Robust, sensitive assays are essential for monitoring proteasome activity and for developing inhibitors of the proteasome. Peptide-conjugated fluorophores are widely used as substrates for monitoring proteasome activity, but fluorogenic substrates can exhibit significant background and can be problematic for screening because of cellular autofluorescence or interference from fluorescent library compounds. Furthermore, fluorescent proteasome assays require column-purified 20S or 26S proteasome (typically obtained from erythrocytes), or proteasome extracts from whole cells, as their samples. To provide assays more amenable to high-throughput screening, we developed a homogeneous, bioluminescent method that combines peptide-conjugated aminoluciferin substrates and a stabilized luciferase. Using substrates for the chymotrypsin-like, trypsin-like, and caspase-like proteasome activities in combination with a selective membrane permeabilization step, we developed single-step, cell-based assays to measure each of the proteasome catalytic activities. The homogeneous method eliminates the need to prepare individual cell extracts as samples and has adequate sensitivity for 96- and 384-well plates. The simple “add and read” format enables sensitive and rapid proteasome assays ideal for inhibitor screening.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Adams J et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Can Res 59:2615–2622
Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9–16
Voorhees PM, Dees EC, O’Neil B et al (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316–6325
Burger AM, Seth AK (2004) The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 4:2217–2229
Goldberg AL (2012) Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 199:583–588
Kisselev AF, van der Linden WA, Overkleeft HS (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19:99–115
Gu Z, Nakamura D, Yao D et al (2005) Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson’s disease. Cell Death Diff 12:1202–1204
Willis MS, Townley-Tilson WHD, Kang EY et al (2010) Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 106:463–478
Baumeister W, Walz J, Zühl F, Seemüller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367–380
Wolf DH, Hilt W (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochem Biophy Acta 1695:19–31
Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428
Rajkumar SV, Richardson PG, Hideshima T et al (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630–639
Nussbaum AK, Dick TP, Keilholz W et al (1998) Cleavage motifs of the yeast 20S proteasome β subunits deduced from digest of enolase I. Proc Natl Acad Sci U S A 95:12504–12509
Rechsteiner M, Hill CP (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15:27–33
Kisselev AF, Kaganovich D, Goldberg AL (2002) Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20S proteasomes. J Biol Chem 277:22260–22270
Kisselev AF, Garcia-Calvo M, Overkleeft HS et al (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278:35869–35877
Ciechanover A (2005) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Diff 12:1178–1190
Chauhan D, Hideshima T, Anderson KC (2005) Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45:465–476
Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407–419
Blackburn C, Gigstad KM, Hales P et al (2010) Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit. Biochem J 430:461–476
Obaidat A, Weiss J, Wahlgren B et al (2011) Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. J Pharmacol Exp Ther 337:479–486
Thompson JL (2013) Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother 47:56–62
Richardson PG, Barlogie B, Berenson J et al (2003) Phase 2 study of bortezomib in relapsed, refractory myeloma. New Eng J Med 348:2609–2617
Agyin JK, Santhamma B, Nair HB et al (2009) BU-32: a novel proteasome inhibitor for breast cancer. Breast Cancer Res 11:R74
Roth P, Kissel M, Herrmann C et al (2009) SC68896, A novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clin Cancer Res 15:6609–6618
Kupperman E, Lee EC, Cao Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70:1970–1980
Papandreou CN, Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Can Res 64:5036–5043
Leytus SP, Melhado LL, Mangel WF (1983) Rhodamine-based compounds as fluorogenic substrates for serine proteinases. Biochem J 209:299–307
Liu J, Bhalgat M, Zhang C et al (1999) Fluorescent molecular probes V: a sensitive caspase-3 substrate for fluorometric assays. Bioorg Med Chem Lett 9:3231–3236
Grant SK, Sklar JG, Cummings RT (2002) Development of novel assays for proteolytic enzymes using rhodamine-based fluorogenic substrates. J Biomol Screen 7:531–540
O’Brien MA, Daily WJ, Hesselberth PE et al (2005) Homogeneous, bioluminescent protease assays: caspase-3 as a model. J Biomol Screen 10:137–148
Moravec RA, O’Brien MA, Daily WJ et al (2009) Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem 387:294–302
Lightcap ES, Mccormack TA, Pien CS et al (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673–683
Kisselev AF, Goldberg AL (2005) Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 398:364–378
Kisselev AF, Callard A, Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281:8582–8590
Fenteany G, Standaert RF, Lane WS et al (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726–731
Dick L, Cruikshank A, Grenier L et al (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J Biol Chem 271:7273–7276
Dick L, Cruikshank A, Destree AT et al (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182–188
Meng L, Mohan R, Kwok BHB et al (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci U S A 96:10403–10408
Corey EJ, Li W-DZ (1999) Total synthesis and biological activity of lactacystin, omuralike and analogs. Chem Pharm Bull 47:1–10
Strucksberg KH, Tangavelou K, Schröder R et al (2010) Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age. Anal Biochem 399:225–229
Acknowledgements
The authors wish to thank our colleagues at Promega Biosciences, Michael Scurria, Laurent Bernad, Bill Dailey, and James Unch, for synthesizing the bioluminescent proteasome substrates. We are indebted to Keith Wood and Dieter Klaubert for the homogeneous, bioluminescent assay concept. We also thank Kay Rashka, Sandra Hagen, Jeri Culp, Debra Lange, Brian McNamara, Anissa Moraes, and Pam Guthmiller for translating the concepts into products.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
O’Brien, M.A., Moravec, R.A., Riss, T.L., Bulleit, R.F. (2015). Homogeneous, Bioluminescent Proteasome Assays. In: Mor, G., Alvero, A. (eds) Apoptosis and Cancer. Methods in Molecular Biology, vol 1219. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1661-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1661-0_9
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1660-3
Online ISBN: 978-1-4939-1661-0
eBook Packages: Springer Protocols